SELECTED PUBLICATIONS
As this sampling of his published work shows, Dr. LaMattina is more than a pundit and continues to be on the front lines of drug discovery and development.
2023
LaMattina, J.L. et al. “IRA – Saving Money, or Playing Politics?", Vital Transformation, September 13, 2023.
2023
LaMattina, J.L. “Unprecedented times call for investment in innovation", CT Examiner, May 18, 2023.
2022
LaMattina, J.L. “Why the IRA will drive up the country’s drug bill — not lower it”, PharmaVoice, November 14, 2022.
2022
LaMattina, J.L. “A Misguided Idea to Turn Over COVID Intellectual Property to Foreign Countries”, CT Examiner, October 21, 2022.
2022
LaMattina, J.L. “Senate Bill 355 Would Divert Patient Savings to For-Profit Businesses”, CT Examiner, April 30, 2022.
2022
LaMattina, J.L. “Bill to Reduce Drug Costs Leaves Out Responsible Players, Risks Region’s Biotech Industry", CT Examiner, March 21, 2022.
2017
LaMattina, J.L. “Approving New Drugs”, Science, 2017, Volume 355, 777.
2016
LaMattina, J. L. “Lessons From Decades of R&D Management”, Medicinal Chemistry Reviews, 2016, Volume 51, 3.
2016
Hwang, Thomas J.; LaMattina, J. L. “Measuring the Value of New Medications and Implications for Medicare’s Proposed Part B Drug Payment Model”, JAMA Oncology, 2016; 2 (9): 1125-1126.
2015
Hensley, P; LaMattina, J. L. “A Plan for Sustainable Funding for U.S. Biomedical Research”, Nature Reviews Drug Discovery, February 2015, Volume 14, Number 2, p147.
2011
LaMattina, J. L. “The Impact of Mergers on Pharmaceutical R&D”, Nature Reviews Drug Discovery, 2011, 10, 559-560.